Psychedelic Safety & Research

Why the Trump Psychedelics Executive Order Makes This the Most Important Moment to Join the Healing Health Alliance

Something happened in Washington last week that changes the economics of running a ketamine or psychedelic-adjacent clinic in America. President Trump’s April 18, 2026 executive order — Accelerating Medical Treatments for Serious Mental Illness — formally directed the FDA to expedite review of psychedelic therapies, instructed the DEA to remove administrative barriers to research and […]

Is Ibogaine Safe? Cardiac Risks, the Magnesium Protocol, and What the Stanford Data Shows

Ibogaine's cardiac risk is real. The Stanford MISTIC protocol has reshaped the picture. A complete 2026 guide to screening, monitoring, and clinic red flags.

Right to Try Ibogaine: What the New Federal Pathway Actually Offers — and What It Doesn’t

The new federal Right to Try pathway for ibogaine explained: who qualifies, what has to happen first, and why it won't be a prescription in 2026.

What Trump’s Psychedelics Executive Order Actually Means for Ibogaine

It is the most significant federal action on psychedelic medicine ever taken by a U.S. president. And Ibogaine is named twice in the text.

How Psychedelics May Rewire the Brain, According to a Major New Scan Analysis

Researchers combined more than 500 scans and found that psychedelics all pushed the brain toward a similar pattern of activity.

Imaging Study Reveals How Ketamine Fights Depression at the Receptor Level

A new PET imaging study provides the first direct evidence that ketamine normalizes AMPA receptor density in the brains of patients with treatment resistant depression.

The Fastest Way to Add Spravato to Your Clinic

The fastest (and cheapest) way to start adding Spravato treatments to your clinic. Our AI assistant save clinics weeks of headaches.

Psilocybin Outperforms Nicotine Patches in Landmark Smoking Study

One dose of psilocybin gave smokers more than six times better odds of quitting than a nicotine patch.

New RAND Data Shows More Americans Are Open To Psychedelics, But in Clinical Settings

Americans are warming to psychedelics, and the shift is rooted in something deeply personal: the desire for better treatment options.

New Grants Are Pushing Psychedelic Therapy Into End of Life Care

Seven organizations across the country received a combined $566,260 to advance research and training in this emerging field.